Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brazikumab in Moderately to Severely Active Ulcerative Colitis (EXPEDITION OLE)
NCT04277546Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Mar 2020
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of brazikumab in ulcerative colitis (UC), sponsored by AstraZeneca. Started Mar 2020; status: terminated.
02
Drugs
brazikumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04277546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04277546.